ALNEV fundamentals
Key facts
Market capitalization624.24 KEUR
Basic EPS (TTM)−33,203.52EUR
Founded1992
CEOHugo Brugière
Websiteneovacs.fr
About
Neovacs SA is a biotechnology company focused on therapeutic vaccines targeting the treatment of autoimmune diseases. The firm is developing a product portfolio using its Kinoid technology through self-antigens, which cause autoimmune or inflammatory diseases. Its product portfolio includes IFNa kinoid, IL-4/13 kinoid, and IgE kinoid. The company was founded by Daniel Zagury on April 16, 1993 and is headquartered in Paris, France.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
−13,000%
−10,000%
−7,000%
−4,000%
−1,000%
H1 '22
H1 '23
H2 '23
H1 '24
H2 '24
−33.00 M
−22.00 M
−11.00 M
0.00
11.00 M
Revenue
Net income
Net margin %
Revenue breakdown
Revenue streams and regions a business earns money from
Dividends
Dividend yield, history and sustainability
No dividends
ALNEV has never paid dividends and has no current plans to do so.
Financial health
Financial position and solvency of the company